C21 Investments Inc. (CNSX: CXXI)
Health Care · Pharmaceuticals · CA
CA$0.39
+4.05% today · -28.7% 1Y
C21 Investments Inc. (CNSX: CXXI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $33.16M and employs 114 people.
Over the last twelve months the share price has lost 28.7%, trading between 0.27 and 0.68.
Tweenvest scores C21 Investments Inc. across four factors: quality 58/100, value 48/100, growth 3/100. Its strongest factor is quality.
CXXI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.16M
- Revenue (TTM)
- $31.69M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 1.88
- 52-week high
- CA$0.68
- 52-week low
- CA$0.27
- Avg volume (3M)
- —
- Shares outstanding
- 118.62M
- Employees
- 114
- Next earnings
- —
About C21 Investments Inc.
C21 Investments Inc. operates as a comprehensive enterprise within the cannabis sector, handling the cultivation, processing, distribution, and retail of consumer goods derived from cannabis and hemp throughout the United States. Its diverse product lineup includes both pre-packaged and bulk cannabis flower, vaporizer cartridges, concentrated extracts, edible products, pre-rolled joints, liquid tinctures, and topical applications. In addition, the company provides payroll administration and employee benefits solutions. Originally incorporated in 1987, the firm rebranded to C21 Investments Inc. in November 2017, having previously operated under the name Curlew Lake Resources Inc. Its primary corporate headquarters are situated in Vancouver, Canada.
- ISIN
- CA12675Q1019
- Founded
- 1987
- Listed since
- Aug 8, 1996
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,234.92 | +0.10% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.25 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.27 | -0.12% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.70 | -0.03% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.52 | -0.99% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.